Beyond Air (XAIR) Q4 2026 Earnings Call Transcript
Beyond Air (XAIR) reported fiscal 2026 revenue of $7.7 million (+107%) and Q4 revenue of $1.9 million (+66%). Management cited ~90% customer renewal and expects CY 2026 revenue guidance of $8 million and CY 2027 of $16–$18 million. Gross profit was $0.3 million vs a prior-year loss; net loss was $33.2 million. The company also approved a 1-for-20 reverse stock split and guided on Gen 2 regulatory approval as a key catalyst.
How this was made
The 30-second read
Why it matters
Investors can reprice the probability-weighted path to Gen 2 approval/launch using the disclosed CY2026 and CY2027 revenue targets, plus the operational improvements (gross profit turn, lower R&D/SG&A) and liquidity runway (cash, equity line).
Market read
The call provides concrete revenue guidance and a catalyst timeline (Gen 2 approval/launch) that can drive repricing, alongside a dilution/liquidity-related corporate action (reverse split).
What to watch
Reverse split may signal compliance pressure and can affect liquidity/holder base; cash burn and long-term debt remain meaningful relative to the company’s scale.
Background
Beyond Air reported FY2026 results and discussed a shift to focus on its LungFit PH platform while positioning Gen 2 as the key near-term catalyst.
Ticker impact
Beyond Air guided CY2026 revenue to $8M and CY2027 to $16M–$18M, tied to pending Gen 2 regulatory approval and commercial launch assumptions.
Near-term volatility likely around Gen 2 regulatory/launch expectations and dilution-compliance overhang; upside bias if investors view guidance as credible.
Multiple forward-looking datapoints (CY2026/CY2027 guidance, Gen 2 catalyst, and reverse split timing) provide actionable framing, but the excerpt is a transcript and the magnitude of market reaction depends on prior expectations and subsequent regulatory updates.
Market effects
Highlights how FDA labeling expansion (transport use) and GPO/IDN access can materially change adoption curves for neonatal respiratory devices.
No specific regional macro impacts disclosed beyond domestic vs international demand commentary.
Mentions regulatory clearance in 45+ countries, implying broader commercialization optionality if Gen 2 expands indications.
Counterpoint
Guidance is heavily dependent on Gen 2 commercial launch and regulatory approval; if timelines slip, the revenue step-up could disappoint despite cost reductions.
Key entities
- companyBeyond Air
Disclosed FY2026 financials, CY2026/CY2027 revenue guidance, and Gen 2 PMA supplement catalyst; approved 1-for-20 reverse split for Nasdaq compliance.
- productLungFit PH
Core nitric oxide delivery system management says it will prioritize for commercial growth.
- product/regulatoryGen 2 system (PMA supplement)
Management’s near-term catalyst; approval would broaden market access to transport services.
- distributionGroup purchasing organizations (GPOs)
Management cites multiple national purchasing agreements to drive hospital evaluations and adoption.
